The European Medicines Agency has issued guidance explaining how good clinical practice (GCP) inspections requested by its human drugs evaluation committee, the CHMP, will be conducted remotely on a case-by-case basis during the COVID-19 pandemic.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?